KRONOX Lab Sciences Limited has announced the publication of its unaudited financial results for the quarter and nine months ended December 31, 2025. The pharmaceutical company has completed its regulatory disclosure requirements following the approval of these results by its Board of Directors.

Board Approval and Regulatory Compliance

The Board of Directors of KRONOX Lab Sciences Limited approved the unaudited standalone financial results at their meeting held on February 14, 2026. This approval came based on recommendations from the company's Audit Committee, ensuring proper governance oversight of the financial reporting process.

Newspaper Publication Requirements

Pursuant to Regulation 47 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the company published its financial results in designated newspapers. The results appeared in Indian Express (English) and Financial Express (Gujarati) on February 16, 2026, ensuring compliance with multilingual publication requirements.

Result Accessibility

The company has made the unaudited financial results readily accessible through multiple channels:

• Company website at https://www.kronoxlabsciences.com/investors/quarterly-results/
• Quick Response (QR) code for digital access
• Stock exchange websites as per regulatory requirements

Corporate Information

KRONOX Lab Sciences Limited operates from its registered office located at Block No. 353, Village: Ekalbara, Taluka: Padra, District: Vadodara - 391440, Gujarat. The company maintains its corporate office at Block No. 284, Village: Dabhasa, Taluka: Padra, District: Vadodara, Gujarat State - 391440.

The announcement was signed by Ketan Ramani, Whole-time Director (DIN: 01510833), and Nikhil Goswami, Company Secretary & Compliance Officer (Membership No. A68272), demonstrating proper corporate authorization and compliance oversight.

KRONOX Lab Sciences Limited has announced its unaudited standalone financial results for the quarter and nine months ended December 31, 2025. The Board of Directors meeting held on February 14, 2026, considered and approved the quarterly financial performance under SEBI Regulation 33.

Q3FY26 Financial Performance

The company demonstrated steady performance in the third quarter with consistent revenue generation and profitability. The quarterly results show the company's operational efficiency in its specialty fine chemicals manufacturing business.

Nine Months Performance Overview

For the nine months ended December 31, 2025, KRONOX Lab Sciences maintained robust financial performance across key metrics. The cumulative results demonstrate sustained growth momentum.

Board Meeting and Regulatory Compliance

The Board of Directors meeting commenced at 2:00 PM and concluded at 2:30 PM on Saturday, February 14, 2026. The board considered and approved the standalone unaudited financial results along with the Independent Auditors' Limited Review Report on Financial Results.

Business Operations

KRONOX Lab Sciences operates in the specialty fine chemicals segment, which represents the company's single reportable segment under Ind AS-108 on Operating Segments. The company focuses on manufacturing high purity specialty fine chemicals from its facilities in Gujarat.

Auditor Review

Mahesh Udhwani & Associates, Chartered Accountants, conducted the limited review of the unaudited financial results. The review was performed in accordance with Standard on Review Engagements (SRE) 2410, and the auditors found no material misstatements in the financial results prepared under applicable accounting standards.